|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
The purpose of this study is to assess the safety and tolerability of different doses of AG019 administered alone or in combination with teplizumab in participants with recent-onset type 1 diabetes (T1D).
100 项与 Precigen ActoBio T1D LLC 相关的临床结果
0 项与 Precigen ActoBio T1D LLC 相关的专利(医药)
100 项与 Precigen ActoBio T1D LLC 相关的药物交易
100 项与 Precigen ActoBio T1D LLC 相关的转化医学